Cargando…
PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431527/ http://dx.doi.org/10.1097/01.HS9.0000850884.42400.6d |
| _version_ | 1784780080047718400 |
|---|---|
| author | Krishnan, A. Nooka, A. K. Chari, A. Garfall, A. Martin, T. Nair, S. Lin, X. Qi, K. Londhe, A. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Usmani, S. |
| author_facet | Krishnan, A. Nooka, A. K. Chari, A. Garfall, A. Martin, T. Nair, S. Lin, X. Qi, K. Londhe, A. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Usmani, S. |
| author_sort | Krishnan, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431527 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94315272022-08-31 PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA Krishnan, A. Nooka, A. K. Chari, A. Garfall, A. Martin, T. Nair, S. Lin, X. Qi, K. Londhe, A. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Usmani, S. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431527/ http://dx.doi.org/10.1097/01.HS9.0000850884.42400.6d Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Krishnan, A. Nooka, A. K. Chari, A. Garfall, A. Martin, T. Nair, S. Lin, X. Qi, K. Londhe, A. Pei, L. Ammann, E. Kobos, R. Smit, J. Parekh, T. Slavcev, M. Usmani, S. PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title | PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2013: teclistamab compared with real-world therapies in patients with triple-class exposed relapsed/refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431527/ http://dx.doi.org/10.1097/01.HS9.0000850884.42400.6d |
| work_keys_str_mv | AT krishnana pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT nookaak pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT charia pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT garfalla pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT martint pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT nairs pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT linx pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT qik pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT londhea pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT peil pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT ammanne pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT kobosr pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT smitj pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT parekht pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT slavcevm pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma AT usmanis pb2013teclistamabcomparedwithrealworldtherapiesinpatientswithtripleclassexposedrelapsedrefractorymultiplemyeloma |